A Dutch neuromodulation developer has raised $60 million to complete the development of its minimally invasive implant for ...

Shares of NeuroPace (NASDAQ:NPCE) shed ~24% in the premarket on Tuesday after the MedTech said that its NAUTILUS study ...

Biomed Israel 2025: the 23rd National Life Science & Technology Week is taking place in Tel Aviv between 20 and 22 May.

Up to 40% of all epilepsy diagnoses in the United States are of the drug-resistant variety, affecting 1.2 million people ...

NeuroPace announced preliminary one-year results from its clinical study evaluating neuromodulation therapy for generalized ...

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. About CVRx, Inc. CVRx is a commercial-stage medical ...

Salvia BioElectronics announced today that it completed a $60 million Series B financing round to support its migraine ...

Urinary and bowel disorders, manifesting as symptoms like frequent urination or difficulty in bowel movements, can greatly ...

Salvia Bioelectronics BV raised $60 million in a series B financing round for its minimally invasive implantable neuromodulation device, Mysalvia therapy, which treats chronic migraine. The funds will ...

Management of Tinnitus in Patients with and without Hearing Loss: A Systematic Review. International Journal of ...